Related Experiment Video

Updated: Aug 24, 2026

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo
11:17

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo

Published on: August 11, 2018

Response to Lauck et al "Cutaneous malignancy after biologic therapy for inflammatory disease: An active comparator,

Sheng Li1, Cheng Chen2

  • 1Department of Anorectal Surgery, Ningbo No.2 Hospital, Ningbo, Zhejiang, China.

Journal of the American Academy of Dermatology
|September 18, 2025
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Janus kinase inhibitorsbiologic therapycutaneous malignancyinflammatory bowel diseasepsoriasisrheumatoid arthritis

More Related Videos

A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)04:11

A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)

Published on: June 9, 2026

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...